Acurx Pharmaceuticals (ACXP)
(Delayed Data from NSDQ)
$5.05 USD
-0.04 (-0.80%)
Updated Aug 6, 2025 03:59 PM ET
After-Market: $5.21 +0.16 (3.18%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACXP 5.05 -0.04(-0.80%)
Will ACXP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACXP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACXP
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y
ACXP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
Other News for ACXP
ACXP Trading Halted as Acurx Pharmaceuticals Awaits News
Acurx Pharmaceuticals trading halted, news pending
Acurx (ACXP) Implements 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing
Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split | ACXP Stock News
Acurx approves 1-for-20 reverse stock split